Clinical trials
Cervical Cancer Recurrent clinical trials
Below are recruiting cervical cancer recurrent clinical trials, each written for real people, not researchers. We’re tracking 172 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05726370RecruitingPhase 2
Pembrolizumab plus chemo before surgery for recurrent head and neck cancer
This Phase 2 trial tests whether giving pembrolizumab (an immune therapy) plus chemotherapy before curative surgery can improve outcomes for people with resectable, recurrent head and neck squamous cell cancer. It also studies how these treatments affect the tumor and immune response using required tissue and blood samples.
Boston, MassachusettsAges 18 years+ - NCT07127822RecruitingPhase 2
Testing a new immunotherapy combo for MSI-H gastric cancer
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) for people with advanced gastric cancer that has a specific DNA repair problem (MSI-H/dMMR). It is for those who have not yet had any treatment for their advanced cancer.
Shijiazhuang, HebeiAges 18 years+ - NCT06660420RecruitingPhase 1
PRAME-targeted NK cells for advanced melanoma
This trial tests a new type of cell therapy using your own immune cells (NK cells) modified to target a protein called PRAME found on melanoma cells. It is for people whose melanoma has not responded to or has returned after standard immunotherapies.
Houston, TexasAges 18 years+ - NCT07560865RecruitingPhase 1
New Cell Therapy for Recurring Brain Cancer
This study tests FT536, a new cell-based treatment, for people with a specific type of brain cancer (WHO Grade 4 astrocytoma) that has come back after standard treatment. The trial combines the new therapy with surgery to see if it can help stop the cancer from growing further.
Minneapolis, MinnesotaAges 18–75 - NCT07495124RecruitingPhase 2
IGFBP-2 vaccine to prevent ovarian cancer return
This trial tests a vaccine that targets a protein called IGFBP-2 to prevent ovarian cancer from coming back. It is for people whose CA-125 blood test shows the cancer might be returning, but who don't yet have tumors visible on scans.
Seattle, WashingtonAges 18 years+ - NCT07475026RecruitingPhase 3
Combination therapy before surgery for high-risk liver cancer
This trial tests whether a combination of two drugs (tislelizumab and lenvatinib) given before surgery can lower the risk of liver cancer coming back in people with early-stage but high-risk disease.
TianjinAges 18–75 - NCT04765098RecruitingPhase 2
Tamoxifen or Etoposide for recurring brain tumor after prior treatment
This trial tests whether tamoxifen works as well as etoposide in people whose glioblastoma has come back after standard chemotherapy and radiation with temozolomide. It aims to find a better medication option for controlling the tumor after the first return.
Edmonton, AlbertaAges 18–65 - NCT07412314Recruiting
Proton Therapy for Recurrent Nasopharyngeal Cancer
This trial uses proton therapy (a precise type of radiation) to treat people whose nasopharyngeal cancer has come back. It aims to see if this treatment can help control the cancer while limiting side effects.
Guangzhou, GuangdongAges 18 years+ - NCT07618624Enrolling by invitationPhase 2
Drug combination before surgery for recurrent head and neck cancer
This trial tests three drugs (finotonlimab, cetuximab, and docetaxel) given before surgery to remove recurrent head and neck cancer in patients whose cancer stopped responding to previous immunotherapy. The goal is to shrink the tumor and improve surgical outcomes.
Foshan, GuangdongAges 18–75 - NCT06532539RecruitingPhase 2
Cadonilimab with radiation for recurrent endometrial cancer
This trial tests a combined treatment of the immunotherapy drug cadonilimab plus radiation and chemotherapy for endometrial cancer that has come back or spread to only a few places. The goal is to see if this combination can help control the cancer better.
Jinan, ShandongAges 18–80 - NCT06448026RecruitingPhase 2
Cemiplimab and cetuximab before surgery for mouth or throat cancer
This trial tests whether combining two targeted drugs (cemiplimab and cetuximab) before surgery can help people with recurrent mouth or throat cancer that has come back after initial treatment. It aims to see if this approach makes surgery more effective.
Houston, TexasAges 18 years+ - NCT07632339RecruitingPhase 2
New drug combination for recurrent head and neck cancer
This trial tests two drugs—becotatug vedotin and pucotenlimab—given before surgery to treat head and neck cancer that has come back in the same area. The goal is to shrink the tumor and help your body's immune system fight the cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05047094Recruiting
DaRT radiation plus pembrolizumab for head and neck cancer
This trial tests whether a targeted internal radiation treatment (DaRT) combined with pembrolizumab (an immune therapy) can shrink recurrent or metastatic head and neck squamous cell cancer that cannot be fully removed with surgery. It may help by making cancer more visible to the immune system while delivering localized radiation to a tumor area.
JerusalemAges 18 years+ - NCT05920863RecruitingPhase 2
Lenvatinib, immunotherapy, plus liver artery treatment before surgery
This Phase 2 trial tests whether giving lenvatinib and immunotherapy along with TACE (a liver artery treatment) before surgery can lower the risk of hepatocellular carcinoma coming back after surgery. It targets people with certain higher-risk early-stage liver tumors (CNLC IB/IIA).
Hangzhou, ZhejiangAges 18–75 - NCT07140679RecruitingPhase 2
Immunotherapy after surgery for certain colon cancers
This trial tests whether giving an immunotherapy drug called toripalimab after surgery can lower the chance of colon cancer coming back. It is for people whose tumors have a specific genetic feature called mismatch repair deficiency (dMMR) and who have had their cancer completely removed.
Atlanta, GeorgiaAges 18 years+ - NCT06326190RecruitingPhase 2
Study of radioactive drug for recurrent meningioma
This trial tests a radioactive drug called 177Lu-DOTATATE for people with recurrent meningioma (a type of brain tumor) that has grown after surgery and radiation. The drug targets a protein on the tumor cells and delivers radiation directly to them.
InnsbruckAges 18 years+ - NCT04991870RecruitingPhase 1
Early-stage immune cell therapy for recurrent grade 4 brain tumors
This Phase 1 trial tests a gene-edited immune cell treatment given into the brain to treat recurrent (returning) grade 4 glioblastoma or related tumors. It aims to find a safe dose and see whether the treatment can slow tumor growth.
Houston, TexasAges 12 years+ - NCT05979064Recruiting
Belly fat graft for recurrent brain tumor
This study tests if a piece of your own belly fat (omentum) placed in the brain during tumor surgery can help fight recurrent glioblastoma. It is for people who are already scheduled for surgery to remove their brain tumor.
New York, New YorkAges 18 years+ - NCT06399640RecruitingPhase 1
Eltanexor and venetoclax for blood cancers
This trial tests a combination of two oral drugs, eltanexor and venetoclax, for people with certain types of blood cancer that have come back or not responded to previous treatment. The goal is to see if this combination can help control the disease.
Memphis, TennesseeAges 18 years+ - NCT07283679RecruitingPhase 1/Phase 2
NK cell therapy with two immune agents for returning lymphoma
This trial tests a new combination of specially grown immune cells (NK cells) plus two drugs that help them attack cancer. It's for people with a type of B-cell lymphoma that came back after at least two prior treatments or a stem cell transplant, and who have either failed or are not eligible for CAR-T cell therapy.
Houston, TexasAges 18 years+ - NCT03739814RecruitingPhase 2
Test inotuzumab, blinatumomab, and possibly ponatinib for CD22 ALL
This Phase 2 study tests a combination of medicines (inotuzumab ozogamicin and blinatumomab), with or without ponatinib, for people with CD22-positive B-cell acute lymphoblastic leukemia (ALL). It aims to improve remission and control leukemia cells, including in the bone marrow.
Birmingham, AlabamaAges 18 years+ - NCT06465316RecruitingPhase 1
Testing teclistamab with iberdomide for relapsed or refractory multiple myeloma
This trial tests a new combination of two drugs (teclistamab and iberdomide) for people with multiple myeloma that has come back or stopped responding to standard treatments. The goal is to see how well this combination works and whether it can help control the disease.
Phoenix, ArizonaAges 18 years+ - NCT06662058Recruiting
Remote hearing test for head and neck cancer patients on cisplatin or radiation
This study tests a remote hearing test to monitor hearing changes in patients with head and neck cancer getting cisplatin chemotherapy and/or radiation. The goal is to catch hearing loss early so treatment can be adjusted.
Atlanta, GeorgiaAges 18 years+ - NCT04941716RecruitingPhase 2
Acalabrutinib plus venetoclax for hard-to-treat CLL/SLL
This Phase 2 trial studies whether combining acalabrutinib and venetoclax can shrink or control chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or did not respond to prior treatment. It may help by attacking the cancer using two different medicines together.
Seattle, WashingtonAges 18 years+
Hear when a new Cervical Cancer Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for cervical cancer recurrent?
- Yes. Clin2 currently lists 172 recruiting cervical cancer recurrent studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cervical cancer recurrent trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cervical cancer recurrent trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.